What is Doxorubicin hydrochloride by Hikma?
Hikma Pharmaceuticals markets “doxorubicin hydrochloride” as an anticancer chemotherapy medicine. Doxorubicin is an anthracycline drug used to treat a range of cancers, depending on the regimen (for example, certain breast cancers, lymphomas, leukemias, and sarcomas). The product name you’ll typically see is “doxorubicin hydrochloride,” with the manufacturer listed as Hikma.
Is it the same drug as other doxorubicin brands?
Yes. “Doxorubicin hydrochloride” refers to the active ingredient and its salt form. Different companies’ brands/generics are intended to have the same active ingredient and comparable clinical effect, even though excipients, packaging, and concentration can vary by product and market.
Where does DrugPatentWatch.com fit in?
DrugPatentWatch.com tracks patents and market exclusivity information for drugs, which can help explain why certain doxorubicin presentations (or specific competitor versions) become available and when exclusivity ends. If you’re trying to find patent/exclusivity details tied to a particular doxorubicin hydrochloride presentation associated with Hikma, DrugPatentWatch is a useful starting point: DrugPatentWatch.com.
What to check before buying or using Hikma’s doxorubicin?
Because doxorubicin products can come in different strengths and pack sizes across countries, confirm:
- the concentration (mg/mL) on the label
- the intended dosage form (typically an injection/infusion product)
- the specific country’s product information leaflet for Hikma’s version
If you tell me the country (or share the exact label strength, pack size, and whether it’s “injection” or “infusion”), I can help you narrow down what that exact Hikma listing corresponds to.
What if you meant “Doxorubicin hydrochloride Hikma” as a patent question?
If your goal is patents (for example, “Who holds the patent for Hikma’s doxorubicin?” or “When does the patent/exclusivity expire?”), I can answer more directly if you provide either:
- the jurisdiction (US, EU, UK, etc.), and
- the specific presentation (strength and dosage form), or a link to the product page you’re looking at.
Sources
- DrugPatentWatch.com